Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1C, P.O. Box 1627, FI70211 Kuopio, Finland.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1C, P.O. Box 1627, FI70211 Kuopio, Finland.
Diabetes Res Clin Pract. 2018 Jul;141:264-274. doi: 10.1016/j.diabres.2018.05.012. Epub 2018 May 17.
Body iron inhibits the metabolism of adiponectin, an insulin sensitizing adipokine. We investigated the relationships of baseline and average of 4-year change in values of serum adiponectin (sA), serum ferritin (sF) and sA/sF ratio on type 2 diabetes (T2D) risk and insulin sensitivity (Matsuda ISI) and secretion (disposition index; DI).
Prospective analyses were conducted in participants with impaired glucose tolerance of the Finnish Diabetes Prevention Study (n = 516) recruited in 1993-1998. Cox and linear regression analyses were used to investigate the associations of sA, sF and sA/sF ratio, as continuous variables, with incident T2D, Matsuda ISI, and DI.
During the mean follow-up of 8.2 years, 157 incident T2D cases occurred (intervention group, n = 65 and control group, n = 92). In adjusted models, baseline sA and sA/sF ratio were inversely associated with T2D risk (HR = 0.49, 95% CI 0.31-0.76, P = 0.002 and HR = 0.83, 95% CI 0.70-0.99, P = 0.044, respectively). Furthermore, a direct association was observed with Matsuda ISI (β=0.13, 95% CI 0.03-0.22, P = 0.009, for sA and β=0.04, 95% CI 0.01-0.07, P = 0.035, for sA/sF ratio) during the average 4-year follow-up. The changes in sA and sA/sF ratio were also inversely associated with T2D risk (HR = 0.36, 95% CI 0.20-0.63, P < 0.001 and HR = 0.76, 95% CI 0.62-0.92, P = 0.006, respectively), and directly with Matsuda ISI (β=0.27, 95% CI 0.17-0.38, P < 0.001, for sA and β=0.07, 95% CI 0.03-0.11, P < 0.001, for sA/sF ratio). No consistent associations were found with DI CONCLUSIONS: Baseline levels and changes during the follow-up in sA and sA/sF ratio are related to T2D risk and insulin sensitivity.
体内铁会抑制脂联素的代谢,脂联素是一种具有胰岛素增敏作用的脂肪因子。我们研究了血清脂联素(sA)、血清铁蛋白(sF)和 sA/sF 比值的基线值和 4 年变化平均值与 2 型糖尿病(T2D)风险和胰岛素敏感性(Matsuda ISI)和分泌(处置指数;DI)的关系。
在芬兰糖尿病预防研究(n=516)中,对葡萄糖耐量受损的参与者进行了前瞻性分析,该研究于 1993-1998 年招募。使用 Cox 和线性回归分析来研究 sA、sF 和 sA/sF 比值作为连续变量与 T2D 发病、Matsuda ISI 和 DI 的相关性。
在平均 8.2 年的随访期间,发生了 157 例 T2D 病例(干预组,n=65;对照组,n=92)。在调整后的模型中,基线 sA 和 sA/sF 比值与 T2D 风险呈负相关(HR=0.49,95%CI 0.31-0.76,P=0.002 和 HR=0.83,95%CI 0.70-0.99,P=0.044)。此外,在平均 4 年的随访期间,还观察到与 Matsuda ISI 呈直接关联(sA 为 β=0.13,95%CI 0.03-0.22,P=0.009,sA/sF 比为 β=0.04,95%CI 0.01-0.07,P=0.035)。sA 和 sA/sF 比值的变化也与 T2D 风险呈负相关(HR=0.36,95%CI 0.20-0.63,P<0.001 和 HR=0.76,95%CI 0.62-0.92,P=0.006),与 Matsuda ISI 呈直接相关(sA 为 β=0.27,95%CI 0.17-0.38,P<0.001,sA/sF 比为 β=0.07,95%CI 0.03-0.11,P<0.001)。与 DI 无一致关联。
基线水平和随访期间 sA 和 sA/sF 比值的变化与 T2D 风险和胰岛素敏感性有关。